RecruitingPhase 4NCT05995600

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE

Studying Antiphospholipid syndrome

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Seoul National University Hospital
Principal Investigator: Seung-Hoon Lee, MD, PhD
Seoul National University Hospital
Intervention: Antiplatelet Drug(drug)
Enrollment: 200 enrolled
Eligibility: 19 years · All sexes
Timeline: 2024 – 2029

Study locations (30)

Hallym University Sacred Heart Hospital, Anyang, South Korea
Busan Paik Hospital, Busan, South Korea
Pusan National University Hospital, Busan, South Korea
Chungbuk National University Hospital, Cheongju-si, South Korea
Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, South Korea
Kangwon National University Hospital, Chuncheon, South Korea
Keimyung University Dongsan Medical Center, Daegu, South Korea
Yeungnam University Medical Center, Daegu, South Korea
Chungnam National University Hospital, Daejeon, South Korea
Hanyang University Guri Hospital, Guri-si, South Korea
Chonnam National University Hospital, Gwangju, South Korea
Chosun University Hospital, Gwangju, South Korea
Gachon University Gil Medical Center, Incheon, South Korea
Inha University Hospital, Incheon, South Korea
Jeju National University Hospital, Jeju City, South Korea
+15 more locations on ClinicalTrials.gov

Collaborators

Samjin Pharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05995600 on ClinicalTrials.gov

Other trials for Antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Antiphospholipid syndrome →

← Back to all trials